Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 24, 2009

Kyoto Buys Fluidigm’s Technology to Research Stem Cell Reprogramming

  • Kyoto University’s Center for iPS Cell Research and Application (CiRA) purchased Fluidigm’s BioMark™ System to use in researching stem cell reprogramming.

    CiRA is using the microfluidic properties of BioMark’s integrated fluidic circuits to analyze selected genes in induced pluripotent stem (iPS) cells. The institute is also using the system to quantify copies of specific genes transferred into a cell to generate iPS cells.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »